1. Home
  2. BRW vs CCCC Comparison

BRW vs CCCC Comparison

Compare BRW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRW

Saba Capital Income & Opportunities Fund SBI

HOLD

Current Price

$6.72

Market Cap

283.1M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.70

Market Cap

185.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRW
CCCC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.1M
185.1M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
BRW
CCCC
Price
$6.72
$2.70
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.20
AVG Volume (30 Days)
265.0K
2.2M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
$6.38
$1.09
52 Week High
$8.49
$3.82

Technical Indicators

Market Signals
Indicator
BRW
CCCC
Relative Strength Index (RSI) 63.63 52.95
Support Level $6.40 $2.26
Resistance Level $7.10 $2.85
Average True Range (ATR) 0.08 0.20
MACD 0.03 -0.04
Stochastic Oscillator 83.75 64.84

Price Performance

Historical Comparison
BRW
CCCC

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: